Low vs higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes
Diabetes · primary immunosuppression in kidney transplant recipients
Low probably leads to lower diabetes compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).
1 finding from 1 review
- Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes onlyRR 0.69 [0.51, 0.93]6 studies · 2125 participantsModerate